Zusammenfassung
Diuretika werden zur Behandlung von Erkrankungen eingesetzt, bei denen das therapeutische Ziel die Verminderung des Extrazellulärvolumens durch Vermehrung der Ausscheidung von Salz und Wasser ist. Die Hauptindikationen sind arterielle Hypertonie, Herzinsuffizienz sowie Ödeme kardialer, hepatischer und renaler Genese.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Chobanian AV, Bakris GL, Black HR, Cushman WC et al (2003):The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289: 2560–2571.
Cosin J, Diez J, TORIC investigators (2002): Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 4: 507–513.
Düsing R, Piesche L (1990): Second line therapy of congestive heart failure with torasemide. Prog Pharmacol Clin Pharmacol 8: 105–120.
Gentilini P, Laffi G, La Villa G, Carloni V, Foschi M, Romanelli RG, Marra F (1993): Torasemide in the treatment of patients with cirrhosis and ascites. Cardiovasc Drugs Ther 7 (Suppl 1): 81–85.
Jacob MS, Tang WH (2011): Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF. Curr Heart Fail Rep. 8(1): 7–13.
Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004): Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543–551.
Lachaine J, Beauchemin C, Ramos E (2011): Use, tolerability and compliance of spironolactone in the treatment of heart failure. BMC Clin Pharmacol 2011 May 20; 11(1): 4 [Epub ahead of print].
Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM et al (2001): Open label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 111: 513–520.
Oßwald H, Vallon V, Luippold G, Gleiter CH (2004): Diuretika - Physiologie, Pharmakologie und klinische Anwendungen. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
Pitt B, Nicklas J (2009): Loop diuretics in patients with heart failure: time to change to torsemide? J Cardiovasc Pharmacol 53: 435–437.
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators (2003): Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309–1321.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999): The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709–717.
Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS (2003): Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289: 2534–2544.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2003). Major outcomes in high-risk hypertensive patients randomized to angiotensin- converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997.
Wargo KA, Banta WM (2009): Acomprehensive review of the loop diuretics: Should furosemide be the first line? Ann Pharmacother 43: 1836–1847.
Wilcox CS (2002): New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 13: 798–805.
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group (2011): Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364: 11–21.
Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL (2006): Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 48: 219–224.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin, Heidelberg
About this chapter
Cite this chapter
Osswald, H., Mühlbauer, B. (2013). Diuretika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2013. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37124-0_23
Download citation
DOI: https://doi.org/10.1007/978-3-642-37124-0_23
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-37123-3
Online ISBN: 978-3-642-37124-0
eBook Packages: Medicine (German Language)